Premium
Outcome of chronic lymphocytic leukemia patients who switched from either ibrutinib or idelalisib to alternate kinase inhibitor: A retrospective study of the French innovative leukemia organization (FILO)
Author(s) -
Godet Sophie,
Protin Caroline,
Dupuis Jehan,
Dartigeas Caroline,
Bastie JeanNoël,
Herbaux Charles,
Leblond Véronique,
de Guibert Sophie,
Ghez David,
Brion Annie,
Ysebaert Loïc,
Delmer Alain,
Quinquenel Anne
Publication year - 2018
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.24981
Subject(s) - ibrutinib , idelalisib , ofatumumab , discontinuation , medicine , chronic lymphocytic leukemia , oncology , leukemia
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom